Market Flux Event

SELLAS Life Sciences Cancer Vaccine Cuts AML Death Risk 41% in Phase 3 Trial, Stock Triples

Read this in the Market Flux app

SELLAS Life Sciences reported that its immunotherapeutic cancer vaccine galinpepimut-S (GPS) met the primary endpoint of its pivotal Phase 3 REGAL trial, reducing the risk of death by 41% compared with best available treatment in patients with acute myeloid leukemia (AML) in second or later remission who were ineligible for stem cell transplant. The result carried a statistically significant hazard ratio of 0.59 (p=0.035). Median overall survival in the 126-patient trial reached 24.0 months for GPS recipients versus 14.7 months for those on best available treatment, a difference of 9.3 months.

GPS, licensed from Memorial Sloan Kettering Cancer Center, is designed to stimulate the immune system to attack residual leukemia cells expressing the WT1 protein. The vaccine was generally well tolerated, with side effects described as mostly mild to moderate and limited primarily to injection-site reactions, and no new safety signals were identified. Full secondary endpoint data are still pending.

Shares of SELLAS surged more than 200% to 300% on the news, with the company's market capitalization reaching approximately 6 billion dollars intraday. SELLAS said it plans to meet with the FDA to discuss an accelerated filing strategy, with a submission for approval targeted in the first half of 2027.

© AI-generated summary is provided by Market Flux

Sources

  1. ReutersSellas' cancer vaccine extends survival in blood cancer trial
  2. BioStocks$KPTIQ Karyopharm FDA Accepts sNDA for XPOVIO (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis PDUFA 06/28/27
  3. Briefingcom$SLS: Sellas Life Sciences reported that Phase 3 REGAL met its primary endpoint, with GPS reducing AML patients' death risk by 41%.
  4. Wallstengine$SLS +300% (Market cap: ~$6B) Sellas Life Sciences' experimental cancer vaccine extended survival in a pivotal Phase 3 leukemia trial, meeting its primary endpoint. Its vaccine, galinpepimut-S (GPS), reduced the risk of death by 41% compared with the best available treatment in patients with acute myeloid leukemia (AML), with a statistically significant hazard ratio of 0.59 (p=0.035). Median overall survival: • GPS vaccine: 24.0 months • Best available treatment: 14.7 months That's a 9.3-month improvement in median survival. The 126-patient REGAL trial focused on AML patients in their second or later remission who were unable to undergo a stem cell transplant, a group with limited treatment options. Licensed from Memorial Sloan Kettering, GPS is designed to stimulate the immune system to target residual leukemia cells expressing the WT1 protein. The vaccine was generally well tolerated, with mostly mild to moderate side effects, primarily injection-site reactions. No new safety concerns were identified. Sellas now plans to meet with the FDA to discuss an accelerated filing strategy, targeting a submission for approval in the first half of 2027. Full secondary endpoint results are still pending, and the vaccine remains investigational.
  5. OpenOutcrier$SLS (+234.7% pre) SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia
  6. Seeking AlphaSELLAS surges on late-stage trial win for cancer vaccine
  7. Business WireAcadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
  8. NasdaqSELLAS Life Sciences Group, Inc. Announces Positive Phase 3 REGAL Trial Results for Galinpepimut-S
Show 8 more
  1. Globe News WirePriavoid Announces Topline Phase 2 Data for Oral All-D-Peptide PRI-002 in Alzheimer’s Disease at CTAD 2026
  2. BenzingaSELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,
  3. MikeZaccardiSo, in the final month before I'm on Medicare, I'd pay $12,460 in health insurance premiums... which is $7,340 in today's dollars. $141k for the trailing 12m ($84k real) Assuming $570 starting in January 2027, with premiums rising 1% per month through November 2052
  4. InvestingDenali Therapeutics at UBS conference: launch momentum lifts outlook
  5. MarketRebelsGLP-1 drugs are set to create a $126B+ weight-loss market by 2029. They also created a downstream restorative aesthetics market that is already scaling. Dermatology plays, device specialists, and early regenerative platforms are positioned differently. This Rebel Research Report maps the landscape. Download free here:
  6. 24/7 Wall StreetYour “Safe” Health Care ETF Just Got Hit by UnitedHealth Again
  7. CoinpediaSLS Stock Soars More Than 200% After Phase 3 Cancer Vaccine Success: What’s Next for SELLAS Life Sciences?
  8. Proactive_XGrey Matters Health achieves medicare and medicaid enrollment for Florida NovaScan Clinic @algernonpharma #proactiveinvestors #greymettershealth #cse #grey #AlzheimersDisease #Neuroimaging #PETScan